FDA Grants Priority Review to AstraZeneca’s Gastric Cancer Drug Sonesitatug Vedotin

0
17
Susan Galbraith

WILMINGTON–AstraZeneca announced Thursday that the U.S. Food and Drug Administration has accepted its Biologics License Application and granted Priority Review to sonesitatug vedotin (Sone-Ve), an investigational treatment for patients with advanced gastric and related cancers.

The application covers second-line and later treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma whose tumors express the protein Claudin 18.2 (CLDN18.2) in at least 25% of tumor cells.

The FDA is expected to make a regulatory decision during the second quarter of 2027.

Priority Review is granted to drug applications that could offer significant improvements over existing treatments, including advances in safety, effectiveness or patient outcomes.

The regulatory submission is supported by results from the Phase III CLARITY-Gastric01 clinical trial, which demonstrated a 42% reduction in the risk of death among patients treated with Sone-Ve compared with treatments selected by investigators.

Patients receiving Sone-Ve had a median overall survival of 10.6 months, compared with 6.4 months for those receiving alternative therapies.

According to AstraZeneca, the survival benefit was generally consistent across predefined patient subgroups, including those with different levels of CLDN18.2 expression.

“After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options. Sone-Ve is the first ADC targeting Claudin 18.2 to improve overall survival for patients compared to current standard of care in this setting and across a population that encompasses a much broader definition of Claudin 18.2 positivity than for current drugs. This Priority Review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US,” said Susan Galbraith, Executive Vice President of Oncology Hematology Research and Development at AstraZeneca.

Sone-Ve is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a protein found in the stomach lining that has emerged as a potential target for cancer treatment.

The therapy combines an antibody that recognizes CLDN18.2 with a cancer-killing drug, allowing the treatment to deliver its therapeutic payload to cells expressing the target protein.

AstraZeneca estimates that approximately 60% of gastric and GEJ cancers express CLDN18.2 in at least 25% of tumor cells, potentially expanding the number of patients eligible for targeted treatment.

Approximately 7,500 patients in the United States receive second-line or later treatment each year for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric or GEJ cancers.

Gastric cancer remains a significant global health concern and is the fifth most common cancer worldwide, as well as the fifth-leading cause of cancer-related deaths.

Nearly one million people were diagnosed with gastric cancer globally in 2024, with approximately 650,000 deaths attributed to the disease.

Patients diagnosed with advanced or metastatic gastric and GEJ cancers generally face limited treatment options and poor survival outcomes. AstraZeneca noted that fewer than 20% of patients diagnosed at advanced stages survive beyond one year.

The CLARITY-Gastric01 trial is a randomized, multicenter Phase III study evaluating Sone-Ve in patients with advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma.

The study is being conducted at 175 clinical centers across 19 countries in North America, Europe, South America and Asia.

AstraZeneca reported that the treatment’s safety profile was consistent with earlier findings, with no new safety concerns identified.

The company acquired exclusive global development and commercialization rights to Sone-Ve through a licensing agreement with KYM Biosciences in March 2023.

Sone-Ve has also received Orphan Drug Designation from the FDA and the European Commission for gastric and GEJ cancers, along with Breakthrough Therapy Designation in China for second-line gastric cancer treatment.

Regulatory applications based on the CLARITY-Gastric01 findings are currently under review in the European Union, China and several other countries.

Beyond its current application, AstraZeneca is evaluating Sone-Ve in additional clinical studies, including the Phase III CLARITY-Gastric02 trial, which is investigating the therapy in combination with other treatments for previously untreated advanced gastric and related cancers.

The company is also studying Sone-Ve in Phase II trials involving other solid tumors, including CLDN18.2-positive pancreatic and biliary tract cancers.

AstraZeneca recently announced a clinical collaboration with Summit Therapeutics to investigate Sone-Ve in combination with ivonescimab, an investigational therapy targeting PD-1 and VEGF, for gastrointestinal cancers.

The FDA’s upcoming decision will determine whether Sone-Ve can become a new treatment option for patients with advanced gastric and related cancers who have progressed following earlier therapies.

Leave A Reply

Please enter your comment!
Please enter your name here